Document Detail


Management of patients with intrauterine fetal death.
MedLine Citation:
PMID:  9001791     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fetal death incidence is 5-10 per 1,000 births. About 25% of the women who carry a dead fetus for more than 4 weeks will show significant alterations in their coagulation system. The treatment for a patient with endouterine fetal death depends on when the pregnancy is terminated, based on the ecographic fetus age. There were 15,070 births from January 1983 to December 1994 in Department B of the Institute of Obstetrics and Gynecology, University of Torino. We took into consideration the cases ofintrauterine fetal death between the 26th and 40th week before labour. This study is based on a cohort of 57 cases of intrauterine fetal demise from the 24th to the 40th week of pregnancy before spontaneous labour.
Authors:
L Visentin; L Leo; M G Alemanno; S Arduino; R Bellino; M Tessarolo; T Wierdis; A Lanza
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental obstetrics & gynecology     Volume:  23     ISSN:  0390-6663     ISO Abbreviation:  Clin Exp Obstet Gynecol     Publication Date:  1996  
Date Detail:
Created Date:  1997-04-01     Completed Date:  1997-04-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7802110     Medline TA:  Clin Exp Obstet Gynecol     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  263-7     Citation Subset:  IM    
Affiliation:
Dept. B of Gynecology, University of Totino, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortion, Therapeutic* / methods
Cesarean Section
Dilatation and Curettage
Female
Fetal Death*
Humans
Labor, Induced / methods
Pregnancy
Pregnancy Trimester, Second
Pregnancy Trimester, Third

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cervical cerclage in the treatment of cervical incompetence in Zambian women.
Next Document:  DNA testing in familial hypertrophic cardiomyopathy: clinical and laboratory implications.